Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T in Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/Lymphoma
NCT05909527Phase 2Withdrawn
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- May 2023
- Primary completion
- Aug 2028
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD7 CAR-T cells injection in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoints: Dose Limited Toxicity at 28 days, Maximal Tolerable Dose at 28 days and 1 more. Planned start May 2023; status: withdrawn.
02
Drugs
CD7 CAR-T cells injection
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05909527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909527.